ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Pittsburgh, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Leukemia
Cancer
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Pittsburgh, PA, USA:

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Biological: bb2121
Drug: Dexamethasone

Phase 3

Celgene
Celgene

Pittsburgh, Pennsylvania, United States and 59 other locations

and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple...

Enrolling
Multiple Myeloma
Drug: Alnuctamab
Drug: Iberdomide

Phase 1

Juno Therapeutics

Pittsburgh, Pennsylvania, United States and 18 other locations

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...

Active, not recruiting
Multiple Myeloma
Drug: Pomalidomide
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Pittsburgh, Pennsylvania, United States and 181 other locations

Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as in...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Bortezomib

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Pittsburgh, Pennsylvania, United States and 135 other locations

The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to ide...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Lenalidomide

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Pittsburgh, Pennsylvania, United States and 26 other locations

The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to id...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Carfilzomib

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Pittsburgh, Pennsylvania, United States and 30 other locations

maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Iberdomide

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Pittsburgh, Pennsylvania, United States and 281 other locations

The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.

Enrolling
Multiple Myeloma
Drug: JNJ-68284528
Drug: Daratumumab

Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Pittsburgh, Pennsylvania, United States and 47 other locations

The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Pittsburgh, Pennsylvania, United States and 114 other locations

38 (CD38) treatment naive participants with newly diagnosed multiple myeloma who are MRD positive as determined by next generation...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Pittsburgh, Pennsylvania, United States and 72 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems